Could This Drug News Give a Lift to Eli Lilly Stock?
Eli Lillys Rezvoglar could be a cheaper alternative to Sanofis Lantus. The biosimilar could haul in nearly $200 million annually for the pharmaceutical giant. Eli Lilly shares are worthy of their lofty premium to those of its peers.
Sunday, January 1, 2023 at 4:00 pm